Literature DB >> 21796762

Pharmacogenetics, cost of genotyping, and guidelines for individualizing therapy with mercaptopurine in pediatric acute lymphoblastic leukemia.

Gabriele Stocco, Kristine R Crews.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21796762      PMCID： PMC3495615          DOI： 10.1002/pbc.23249

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


× No keyword cloud information.
  11 in total

1.  Assessing the cost-effectiveness of pharmacogenomics.

Authors:  D L Veenstra; M K Higashi; K A Phillips
Journal:  AAPS PharmSci       Date:  2000

2.  Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.

Authors:  M V Relling; E E Gardner; W J Sandborn; K Schmiegelow; C-H Pui; S W Yee; C M Stein; M Carrillo; W E Evans; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

Review 3.  Pharmacogenomics in pediatric leukemia.

Authors:  Steven W Paugh; Gabriele Stocco; William E Evans
Journal:  Curr Opin Pediatr       Date:  2010-12       Impact factor: 2.856

4.  Physicians as guardians of genetic knowledge.

Authors: 
Journal:  Lancet       Date:  2011-03-19       Impact factor: 79.321

5.  A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia.

Authors:  Jennifer R Donnan; Wendy J Ungar; Maria Mathews; Rebecca L Hancock-Howard; Proton Rahman
Journal:  Pediatr Blood Cancer       Date:  2011-02-22       Impact factor: 3.167

6.  Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.

Authors:  M Elske van den Akker-van Marle; David Gurwitz; Symone B Detmar; Christine M Enzing; Michael M Hopkins; Emma Gutierrez de Mesa; Dolores Ibarreta
Journal:  Pharmacogenomics       Date:  2006-07       Impact factor: 2.533

7.  Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient.

Authors:  E Schütz; J Gummert; F Mohr; M Oellerich
Journal:  Lancet       Date:  1993-02-13       Impact factor: 79.321

Review 8.  Pharmacogenetics: from bench to byte--an update of guidelines.

Authors:  J J Swen; M Nijenhuis; A de Boer; L Grandia; A H Maitland-van der Zee; H Mulder; G A P J M Rongen; R H N van Schaik; T Schalekamp; D J Touw; J van der Weide; B Wilffert; V H M Deneer; H-J Guchelaar
Journal:  Clin Pharmacol Ther       Date:  2011-03-16       Impact factor: 6.875

9.  Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism.

Authors:  Mary V Relling; Russ B Altman; Matthew P Goetz; William E Evans
Journal:  Lancet Oncol       Date:  2010-04-21       Impact factor: 41.316

10.  How will GINA influence participation in pharmacogenomics research and clinical testing?

Authors:  L G Dressler; S F Terry
Journal:  Clin Pharmacol Ther       Date:  2009-11       Impact factor: 6.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.